ClinicalTrials.Veeva

Menu

Physiologic Insulin Resensitization (PIR) Treatment in Patients With a Diagnosis of Type 2 Diabetes Mellitus (T2DM)

The University of Alabama at Birmingham logo

The University of Alabama at Birmingham

Status

Not yet enrolling

Conditions

Type 2 Diabetes Mellitus

Treatments

Other: Physiologic insulin resensitization (PIR)

Study type

Interventional

Funder types

Other
Industry
NIH

Identifiers

NCT07906470
1R44DK148354-01 (U.S. NIH Grant/Contract)
Well Cell Global LLC (Other Identifier)
IRB-300017055

Details and patient eligibility

About

The purpose of the study is to assess the outcomes of Physiologic Insulin Resensitization (PIR) treatment compared to standard of care (SOC) on patients with a diagnosis of Type 2 diabetes mellitus (T2DM). Participants will be in this study for 24 to 26 weeks.

Full description

This study will include two cohorts. The assessments include a three-hour intravenous glucose tolerance test (IVGTT) for insulin sensitivity and two types of imaging. The PIR cohort will undergo these assessments at baseline, 12 weeks, and 24 weeks, plus one additional IVGTT at 26 weeks. In addition, the PIR group will be required to undergo a three-hour infusion of insulin once or twice every week for weeks 0-24. The control cohort will undergo insulin sensitivity and body composition assessments at baseline,12 weeks, and 24 weeks.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Is 18 or older (male or female)

  2. Have a documented diagnosis of T2DM of 6 months or greater prior to screening and an HbA1c >7.5. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists.

  3. In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months.

  4. In the opinion of the Investigator, is able to do all of the following:

    • Provide valid informed consent.
    • Understand and comply with study procedures as presented in the consent process.
    • Has the capacity or support to attend all required visits.
  5. If female, the subject must meet either of the following sets of conditions:

    • Is of non-childbearing potential, defined as meeting either of the following criteria:
    • Age ≥50 years and post-menopausal for at least one (1) year
    • Surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
    • Is of childbearing potential and meets both of the following criteria:
    • Has a negative serum pregnancy test (beta-human chorionic gonadotropin) at screening.
    • Agrees to practice an acceptable method of birth control (contraception) from screening until at least 30 days after last study treatment

Exclusion criteria

  1. Has in the past two (2) years received treatment for a malignancy.

  2. Current pregnancy or intends to become pregnant during the study

  3. Has in the past one (1) year used non-prescription opioids or non- prescriptive psychoactive drugs.

  4. Has in the past six (6) months had a hypoglycemic event requiring urgent care and/or administration of glucagon, osteocalcin, or parenteral glucose, unless approved for enrollment by the Medical Monitor.

  5. Has within the past one (1) month participated in a clinical study involving either of the following:

    • An investigational drug or procedure for any clinical indication
    • An investigation method for glucose control using approved agents.
  6. Is nursing or is planning to nurse during the study.

  7. Has - in the opinion of the Investigator - psychiatric, behavioral, cognitive and/or clinical dysfunction (whether or not related to known medical illness or drug / alcohol use) that would affect the subject's safety and/or compliance.

  8. Is on active dialysis at time of screening

  9. Weighs more than 450 lbs or has a waist circumference that exceeds the size of the MR bore when the coil is placed

  10. Has had recent iodine or barium-based contrast imaging

  11. Has an implanted device with metal incompatible with MR scanning, or the presence of any other metal in the body (such as shrapnel)

  12. Is unable to remain still for extended periods of time or to hold breath for 10 seconds

  13. Is claustrophobic.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Standard of Care Cohort (SOC)
No Intervention group
Description:
Patients will continue standard of care treatment for Type 2 Diabetes Mellitus
Standard of Care (SOC) plus Physiologic Insulin Resensitizatioin (PIR) cohort
Experimental group
Description:
Standard of care treatment for Type 2 diabetes mellitus in addition to a matched-pair design (matched for age, BMI, disease duration, A1c, medication) to receive physiologic insulin resensitization (PIR).
Treatment:
Other: Physiologic insulin resensitization (PIR)

Trial contacts and locations

1

Loading...

Central trial contact

Harper Basquill, RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems